Clinical outcomes of vitamin D deficiency and supplementation in cancer patients

Laisa Teleni, Jacqueline Baker, Bogda Koczwara, Michael G Kimlin, Euan Walpole, Kathy Tsai, Elizabeth A Isenring

Research output: Contribution to journalArticleResearchpeer-review

21 Citations (Scopus)

Abstract

Results of recent studies suggest that circulating levels of vitamin D may play an important role in cancer-specific outcomes. The present systematic review was undertaken to determine the prevalence of vitamin D deficiency (<25 nmol/L) and insufficiency (25-50 nmol/L) in cancer patients and to evaluate the association between circulating calcidiol (the indicator of vitamin D status) and clinical outcomes. A systematic search of original, peer-reviewed studies on calcidiol at cancer diagnosis, and throughout treatment and survival, was conducted yielding 4,706 studies. A total of 37 studies met the inclusion criteria for this review. Reported mean blood calcidiol levels ranged from 24.7 to 87.4 nmol/L, with up to 31% of patients identified as deficient and 67% as insufficient. The efficacy of cholecalciferol supplementation for raising the concentration of circulating calcidiol is unclear; standard supplement regimens of <1,000 IU D₃ /day may not be sufficient to maintain adequate concentrations or prevent decreasing calcidiol. Dose-response studies linking vitamin D status to musculoskeletal and survival outcomes in cancer patients are lacking.

Original languageEnglish
Pages (from-to)611-21
Number of pages11
JournalNutrition Reviews
Volume71
Issue number9
DOIs
Publication statusPublished - Sep 2013
Externally publishedYes

Fingerprint Dive into the research topics of 'Clinical outcomes of vitamin D deficiency and supplementation in cancer patients'. Together they form a unique fingerprint.

Cite this